Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Sarepta Therapeutics (SRPT) PT Raised to $33 at Morgan Stanley
July 20, 2017 9:16 AM EDTMorgan Stanley raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $33.00 (from $31.00) while maintaining a Equalweight rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $69 at Cowen Following 'Beat and Raise'
July 20, 2017 6:07 AM EDTCowen analyst Ritu Baral raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $69.00 (from $62.00) while maintaining a Outperform rating following a solid beat and raise for Exondys 51 revenues.
Baral sees continued progress with both prescribers and payors... More
